Literature DB >> 26686510

Evidence-based management of vitiligo: summary of a Cochrane systematic review.

M Whitton1, M Pinart2,3,4,5, J M Batchelor6, J Leonardi-Bee7, U Gonzalez8, Z Jiyad9, V Eleftheriadou6, K Ezzedine10,11,12.   

Abstract

Vitiligo affects around 1% of the world's population. Despite it being relatively common, there is still no effective treatment. The objective of this study was to update the Cochrane systematic review of randomized clinical trials (RCTs) to evaluate the efficacy of treatments for vitiligo. We carried out searches of a range of databases to October 2013 for RCTs of interventions for vitiligo regardless of language or publication status. At least two reviewers independently assessed study eligibility and methodological quality and extracted data using data extraction forms approved by the Cochrane Skin Group. Our primary outcomes of interest were quality of life, > 75% repigmentation and adverse effects. We retrieved 96 studies, of which 39 were new studies, with an overall total of 4512 participants. Repigmentation was assessed in all studies, although only five reported on all three of our primary outcomes. Regarding our two secondary outcomes, six studies measured cessation of spread but none assessed long-term permanence of repigmentation at 2 years' follow-up. Most of the studies evaluated combination treatments, which generally showed better repigmentation than monotherapies. Of the new studies, seven were surgical interventions. The majority of the studies had fewer than 50 participants. The quality of the studies was poor to moderate at best. Very few studies specifically included children or participants with segmental vitiligo. Five years after the last update of this review, there are still important variations in study design and outcome measures in clinical trials for vitiligo, limiting the evidence for the efficacy of different therapeutic options. The best evidence from individual trials showed short-term benefit from topical corticosteroids and various forms of ultraviolet radiation combined with topical preparations. Long-term follow-up and patient-rated outcomes should be incorporated into study design, and more studies should assess psychological interventions.
© 2015 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26686510     DOI: 10.1111/bjd.14356

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  17 in total

Review 1.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

2.  Utility of dermoscopy for evaluating the therapeutic efficacy of tacrolimus ointment plus 308-nm excimer laser combination therapy in localized vitiligo patients.

Authors:  Lu-Mei Wang; Wan-Jiao Lu; Jing-Tao Yuan; Bi-Bing Zeng; Dan Li; Feng Zhang; Jun-Jie Li
Journal:  Exp Ther Med       Date:  2018-02-28       Impact factor: 2.447

3.  Exosomes as a novel pathway for regulating development and diseases of the skin.

Authors:  Ying Liu; Haidong Wang; Juan Wang
Journal:  Biomed Rep       Date:  2018-01-31

Review 4.  Understanding autoimmunity of vitiligo and alopecia areata.

Authors:  Jillian F Rork; Mehdi Rashighi; John E Harris
Journal:  Curr Opin Pediatr       Date:  2016-08       Impact factor: 2.856

5.  Evaluation of treatment response to autologous transplantation of noncultured melanocyte/keratinocyte cell suspension in patients with stable vitiligo.

Authors:  Mariana Gontijo Ramos; Daniel Gontijo Ramos; Camila Gontijo Ramos
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

6.  Network pharmacological mechanisms of Vernonia anthelmintica (L.) in the treatment of vitiligo: Isorhamnetin induction of melanogenesis via up-regulation of melanin-biosynthetic genes.

Authors:  Ji Ye Wang; Hong Chen; Yin Yin Wang; Xiao Qin Wang; Han Ying Chen; Mei Zhang; Yun Tang; Bo Zhang
Journal:  BMC Syst Biol       Date:  2017-11-16

7.  Polygonum multiflorum Thunb. Extract Stimulates Melanogenesis by Induction of COX2 Expression through the Activation of p38 MAPK in B16F10 Mouse Melanoma Cells.

Authors:  Donghee Kim; Hyo-Jin Kim; Hee-Sook Jun
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-25       Impact factor: 2.629

8.  Platelet-rich plasma versus combined fractional carbon dioxide laser with platelet-rich plasma in the treatment of vitiligo: a comparative study.

Authors:  Mostafa Kadry; Abeer Tawfik; Noha Abdallah; Ashraf Badawi; Hisham Shokeir
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-11-08

9.  Home interventions and light therapy for the treatment of vitiligo (HI-Light Vitiligo Trial): study protocol for a randomised controlled trial.

Authors:  Rachel H Haines; Kim S Thomas; Alan A Montgomery; Jane C Ravenscroft; Perways Akram; Joanne R Chalmers; Diane Whitham; Lelia Duley; Viktoria Eleftheriadou; Garry Meakin; Eleanor J Mitchell; Jennifer White; Andy Rogers; Tracey Sach; Miriam Santer; Wei Tan; Trish Hepburn; Hywel C Williams; Jonathan Batchelor
Journal:  BMJ Open       Date:  2018-04-03       Impact factor: 2.692

10.  Mesenchymal stem cells promote human melanocytes proliferation and resistance to apoptosis through PTEN pathway in vitiligo.

Authors:  Lifei Zhu; Xi Lin; Lin Zhi; Yushan Fang; Keming Lin; Kai Li; Liangcai Wu
Journal:  Stem Cell Res Ther       Date:  2020-01-15       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.